Substance Use and Mental Health Comorbidities and Receipt of Specialty Care Among Patients Enrolled in a Low-Barrier HIV Clinic.
HIV
Housing Instability
Mental Disorders
Population Characteristics
Substance-Related Disorders
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
03
06
2023
medline:
9
11
2023
pubmed:
23
6
2023
entrez:
23
6
2023
Statut:
ppublish
Résumé
Low-barrier care is one model of a differentiated service delivery approach for people with HIV (PWH) who are not engaged in conventionally-organized HIV care. Although psychiatric and substance use disorders are common among patients in low-barrier clinics, approaches to behavioral health service delivery within this context have not been well-described. We conducted a descriptive analysis using retrospective review of medical records to evaluate substance use and psychiatric comorbidities and receipt of behavioral health services among patients in the Max Clinic in Seattle, Washington. Among 227 patients enrolled from 2015 to mid-2020, most had a history of hazardous substance use (85%), a psychiatric diagnosis (69%) or unstable housing (69%) documented in the medical record. Less than half of patients referred for depression treatment (33%) or for opioid use disorder treatment (40%) completed even one specialty care visit. More effective approaches are needed to engage patients in behavioral health services within the context of low-barrier HIV care.
Identifiants
pubmed: 37351687
doi: 10.1007/s10461-023-04110-3
pii: 10.1007/s10461-023-04110-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3952-3960Subventions
Organisme : NIMH NIH HHS
ID : P30 MH123248
Pays : United States
Organisme : NIMH NIH HHS
ID : R34 MH124625
Pays : United States
Organisme : NIDA NIH HHS
ID : 1R25DA050985
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.
doi: 10.1016/S0140-6736(10)60829-X
pubmed: 20650518
pmcid: 4855280
Oldfield BJ, Munoz N, McGovern MP, et al. Integration of care for HIV and opioid use disorder. AIDS. 2019;33(5):873–84.
doi: 10.1097/QAD.0000000000002125
pubmed: 30882491
Chuah FLH, Haldane VE, Cervero-Liceras F, et al. Interventions and approaches to integrating HIV and mental health services: a systematic review. Health Policy Plan. 2017;32(suppl4):iv27–iv47.
doi: 10.1093/heapol/czw169
pubmed: 29106512
pmcid: 5886062
Moher M, Erickson M, Black P, et al. Improving Post-Release Care Engagement for People living with HIV involved in the criminal justice system: a systematic review. AIDS Behav. 2022. https://doi.org/10.1007/s10461-021-03513-4 .
doi: 10.1007/s10461-021-03513-4
pubmed: 34705154
Holtzman CW, Shea JA, Glanz K Mapping patient-identified barriers and facilitators to retention in HIV care and antiretroviral therapy adherence to Andersen’s Behavioral Model. AIDS Care., Hartzler B, Dombrowski JC, Crane HM et al. Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States. AIDS Behav. 2017; https://doi.org/10.1007/s10461-016-1584-6.
Hartzler B, Dombrowski JC, Crane HM, et al. Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States. AIDS Behav. 2017; https://doi.org/10.1007/s10461-016-1584-6
Yehia BR, Stewart L, Momplaisir F, et al. Barriers and facilitators to patient retention in HIV care. BMC Infect Dis. 2015. https://doi.org/10.1186/s12879-015-0990-0 .
doi: 10.1186/s12879-015-0990-0
pubmed: 26123158
pmcid: 4485864
Dombrowski JC, Ramchandani M, Dhanireddy S, Harrington RD, Moore A, Golden MR. The Max Clinic: Medical Care designed to engage the hardest-to-Reach Persons living with HIV in Seattle and King County, Washington. AIDS Patient Care STDS. 2018;32(4):149–56.
doi: 10.1089/apc.2017.0313
pubmed: 29630852
pmcid: 5905858
Hickey MD, Imbert E, Appa A, et al. HIV Treatment Outcomes in POP-UP: Drop-in HIV Primary Care Model for People experiencing homelessness. J Infect Dis. 2022. https://doi.org/10.1093/infdis/jiac267 .
doi: 10.1093/infdis/jiac267
pubmed: 35759251
pmcid: 10233499
Palar K, Wong MD, Cunningham WE. Competing subsistence needs are associated with retention in care and detectable viral load among people living with HIV. J HIV AIDS Soc Serv. 2018. https://doi.org/10.1080/15381501.2017.1407732 .
doi: 10.1080/15381501.2017.1407732
pubmed: 30505245
pmcid: 6261356
Wong MD, Sarkisian CA, Davis C, Kinsler J, Cunningham WE. The association between life chaos, health care use, and health status among HIV-infected persons. J Gen Intern Med. 2007. https://doi.org/10.1007/s11606-007-0265-6 .
doi: 10.1007/s11606-007-0265-6
pubmed: 17597350
pmcid: 2219764
Barker B, Adams E, Wood E, et al. Engagement in maximally-assisted therapy and adherence to antiretroviral therapy among a cohort of indigenous people who use illicit drugs. AIDS Behav. 2019;23:1258–66.
doi: 10.1007/s10461-018-2226-y
pubmed: 30269233
pmcid: 6440861
Dombrowski JC, Galagan SR, Ramchandani M, et al. HIV Care for patients with Complex needs: a controlled evaluation of a Walk-In, Incentivized Care Model. Open Forum Infect Dis. 2019;6(7):ofz294.
doi: 10.1093/ofid/ofz294
pubmed: 31341930
pmcid: 6641789
Imbert E, Hickey MD, Clemenzi-Allen A et al. Evaluation of the POP-UP programme: a multicomponent model of care for people living with HIV with homelessness or unstable housing. AIDS. 2021 Jul 1;35(8):1241–1246.
2022 Overdose Death Report. In: King County Fatal Overdose Dashboard. Seattle & King County Public Health. 2022. https://kingcounty.gov/depts/health/overdose-prevention/~/media/depts/health/medical-examiner/documents/2022-overdose-death-report.ashx .
Pyne JM, Fortney JC, Curran GM, et al. Effectiveness of collaborative care for depression in human immunodeficiency virus clinics. Arch Intern Med. 2011;171(1):23–31.
pubmed: 21220657
Pence BW, Gaynes BN, Adams JL, et al. The effect of antidepressant treatment on HIV and depression outcomes: results from a randomized trial. AIDS. 2015;29(15):1975–86.
doi: 10.1097/QAD.0000000000000797
pubmed: 26134881
Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis. 2006;43(Suppl 4):184–90.
doi: 10.1086/508182
Rosecrans A, Harris R, Saxton RE, et al. Mobile low-threshold buprenorphine integrated with infectious disease services. J Subst Abuse Treat. 2022;133:108553.
doi: 10.1016/j.jsat.2021.108553
pubmed: 34238629